Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367637 | 0.83 | PGR (0.70) | PGRESR2ALOX5TAAR1BACE1 | |
| SCHEMBL18874465 | 0.81 | PGR (0.67) | PGR | |
| SCHEMBL6013810 | 0.81 | PGR (0.67) | PGRESR2ALOX5TAAR1MAOB | |
| SCHEMBL4357762 | 0.80 | PGR (0.67) | PGRESR2ALOX5TAAR1BACE1 | |
| SCHEMBL4540489 | 0.79 | PGR (0.65) | PGRESR2ALOX5TAAR1BACE1 | |
| SCHEMBL10802069 | 0.76 | PGR (0.61) | PGRESR2ALOX5TAAR1MAOB | |
| SCHEMBL4352812 | 0.76 | PGR (0.60) | PGRESR2ALOX5TAAR1BACE1 | |
| SCHEMBL5844964 | 0.74 | ALOX5 (0.69) | PGRESR2ALOX5TAAR1BACE1 | |
| SCHEMBL7969111 | 0.73 | CYP3A4 (0.68) | PGRESR2ALOX5TAAR1BACE1 | |
| Methane SCHEMBL11773808 | 0.72 | CYP3A4 (0.65) | PGRESR2ALOX5TAAR1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693103-B2 | CONTRACEPTION, TREATMENT OF FIBROIDS, ANTICARCINOGENIC AND -TUMOR AGENTS (ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER), AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY; BENIGN PROSTATIC HYPERTROPHY; ADENOCARCINOMAS | WYETH | 2004-02-17 | — | — | US | disclosed |
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2002-07-18 | — | — | US | disclosed |
| US-6358948-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS AGAINST BREAST, PITUITARY, OVARIAN, ENDOMETRIUM, AND PROSTATE CANCER; BENIGN PROSTATIC HYPERPLASIA; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-19 | — | — | US | disclosed |
| EP-1175404-A1 | QUINAZOLINONE AND BENZOXAZINE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066560-A1 | QUINAZOLINONE AND BENZOXAZINE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | PGR, NR3C1, NR3C2 | PGR 1/4885ESR2 45/4885ALOX5 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.